Peptide Therapeutics Market Size, Share, Trends and Growth Forecast to 2035

Why Is the Peptide Therapeutics Market Expected to Reach USD 87.21 Billion by 2035?

The global peptide therapeutics market size is calculated at USD 52.59 billion in 2025 and is predicted to increase from USD 56.06 billion in 2026 to approximately USD 87.21 billion by 2035, expanding at a CAGR of 5.19% from 2026 to 2035. Due to rising demand for targeted treatments, advancements in drug delivery technologies, increasing chronic disease prevalence, and expanding research in personalised medicine.

Market Highlights

• North America dominated the market with the highest market share of 45.96% in 2025.
• Asia Pacific is projected to expand at the fastest CAGR of 6.20% between 2026 and 2035.
• By application, the metabolic disorder segment has captured around 22.80% of the market share in 2025.
• By application, the gastrointestinal disorder segment is poised to grow at a CAGR of 6.31% between 2026 and 2035.
• By type, the innovative segment has accounted for more than 60.40% of revenue share in 2025.
• By type, the generic segment is expected to expand at a notable CAGR of 4.76% between 2026 and 2035.
• By route of administration, the parenteral segment has generated more than 76.03% of revenue share in 2025.
• By route of administration, the oral segment is expanding at a CAGR of 6.02% between 2026 and 2035.
• By distribution channel, the hospital pharmacies segment has contributed around 39.90% of the market share in 2025.
• By distribution channel, the online drug stores segment is projected to grow at a CAGR of 5.51% between 2026 and 2035.
• By synthesis technology, the liquid phase peptide synthesis (LPPS) segment has recorded the largest market share of 45.87% in 2025.

Market Overview

Peptide drug market is registering immense growth owing to rising demand for efficacious and precise treatments of chronic diseases like diabetes, obesity, cancer and cardiovascular diseases, high efficacy and enhanced safety of peptides as drug make them important players in the domain of pharmaceutical development.

Developments in peptide synthesis, drug delivery techniques, and biotechnology are driving growth in the market, the increased use of GLP-1 receptor agonists in metabolic conditions and increasing studies related to oncology and rare diseases have promoted pharmaceutical companies to make use investments in peptide drugs.

The outlook of the future of the peptide therapeutics market is very bright due to increased clinical studies, manufacturing capabilities, and advancements in peptide technology, increased investments in healthcare along with the need of customised medications is likely to further spur growth in the industry.

What is the Role of AI in the Peptide Therapeutic Market?

The key benefit of artificial intelligence (AI) algorithms can also improve the synthesis process by predicting the most efficient and cost-effective routes for peptide synthesis. The main benefit of using peptides in therapies is their ability to minimize the impact on healthy cells, allowing for targeted action directly on tumor cells. AI is used in addiction treatment to personalize care plans, predict relapse risks, analyze patient data, and automate administrative tasks. AI systems can identify patterns in behavior and treatment responses, helping clinicians provide tailored interventions that increase the likelihood of successful recovery.

Artificial intelligence in peptide therapeutics includes that we can access an AI therapist chatbot 24/7 with no wait times. AI therapy may be an easier entry point for those who are hesitant to see a therapist, and it is offered at a lower cost compared to human therapy. AI has the potential to transform drug discovery by improving data analysis and prediction, leading to faster and more effective treatments.

Peptide Therapeutics Market Trends

• Technological Boon – The existing and new technology boon features robust structural modification, oral bioavailability, and AI-influenced drug design. With the associated platforms, the delivery efficiency is gaining traction in the market and further establishes the compatible oral delivery technologies.
• Investment Hype in R&D – Active investments in the technology integration, solid-phase peptide synthesis, and targeted drug delivery platforms. The oncology and neurology conditions are paving the way for new studies and discoveries for researchers that instantly attract massive investment from leading companies and regulatory bodies.
• Rising Metabolic and Cancer Conditions – Peptide hormones are popularly used to treat serious and extreme conditions such as cancer and metabolic conditions to stimulate the natural and robust physiological pathway further. This drives the expansion of blockbuster and effective peptides such as Semaglutide.

Market Outlook

• Global Expansion: The global expansion of the market took a transitional change with the evolving traditional hormones involvement, whereas the extremity of gastrointestinal, immunology and metabolic. The modernizations in peptide drug conjugates bring a shift in the drug modality. The tech solutions and efficiency in the supply chain drive a smooth profit into the market spectrum to further contribute to the emerging healthcare needs.
• Startup Ecosystem: The startup is pushed by tech changes and system integration that drive need in the healthcare space for tech experts to justify the increasing manufacturing costs. The growing challenges in the historical bioavailability are opening doors for new startups to bring effective solutions to the table of oral peptide delivery. The support of existing healthcare leaders for startups marks a kind contribution and encouragement to the market enthusiast.
• Sustainability Trends: Sustainability trends in the market are fuelled by green chemistry and AI-influenced predictive design, which presents a commendable blend of combining science and technology. With this, the companies use enzymes specifically for Chemo-enzymatic peptide synthesis. This idea cuts chemical waste and energy consumption and brings green approaches to the healthcare door, serving as a great solution to the market. The iterative technique in the consistent manufacturing space stimulates resource impact and alleviates solvent usage, helping production cycle of peptide.

Market Report Coverage and Key Metrics

Market Dynamics

Drivers

Increasing incidences of metabolic disorders

Peptide drug application in metabolic disorders and discovery strategies. All life activities are dependent on metabolic homeostasis, which is maintained by many biological pathways in the body. In recent years, many peptide drugs for metabolic disorders treatment have become blockbusters in the pharmaceutical market. Metabolic peptides can influence metabolic processes and contribute to both inflammatory and anti-inflammatory responses.

Restraint

High cost of drug development

The high cost of a drug is an expensive prescribed item and represents an inappropriate cost relative to the total cost of the relevant episode in terms of volume and cost. The high cost of drug development is challenging for an industry being pressured to cut costs. It makes it harder to advance new ideas and create new cures. The cost of the medical product to the market has been increasing, and clinical trials constitute a large portion of these costs.

Opportunity

Expansion of minimally invasive therapies

The minimally invasive therapies' benefits include visible scars that are smaller and fewer, reduced costs, quicker return to work, less need for narcotics, fewer respiratory complications, lower bleeding, improved surgical accuracy, decreased risk of muscle damage, accurate procedures, minimal scarring, improved cosmetic outcomes, smaller incisions, lower complication rates, less tissue trauma, faster recovery, reduced blood loss, less scarring, shorter hospital stays, lower risk of infection, and less pain.

Market Segmentation Analysis

Application Insights

Why the Metabolic Disorder Segment Dominates the Peptide Therapeutics Market?

The metabolic disorder segment dominated the peptide therapeutics market in 2025. Due to growing cases of different illnesses such as diabetes and obesity across the globe, the growing demand for peptides medicines such as GLP-1 receptor agonists, has led to an increase in market share of the segment.

Gastrointestinal disorder segment expects the fastest growth in the market during the forecast period. Due to the increasing prevalence of gastrointestinal disorders, increased awareness about innovative therapeutic options, and high demand for novel therapeutics, continuous development of peptides therapeutics for diseases including inflammatory balls diseases and gastrointestinal disorders driving growth of the segment.

Peptide Therapeutics Market Revenue (USD Million), By Application, 2022-2024

Type Insights

Why the Innovative Segment Dominates the Peptide Therapeutics Market?

The innovative segment dominated the peptide therapeutics market in 2025. Because owing to its clinical efficacy, target specificity, and increasing applications in diseases such as diabetes, cancer, and metabolic disorders, innovations in peptide engineering, increased regulatory approvals, R&D spending have made the category even more dominant in the market.

Generic transportation segment expects the fastest growth in the market during the forecast period. Due to account of the expiry of patents of many branded peptide trucks along with growing need for effective treatments at affordable costs, generic peptides offer similar efficacy as that offered by branded drugs but at lower cost, thereby making them an attractive option for the patients.

Route of Administration Insights

Why the Parenteral Segment Dominates the Peptide Therapeutics Market?

The parenteral segment dominated the peptide therapeutics market in 2025. Due to their limited stability and poor absorption through oral administration, injectable forms of medication ensure better bioavailability and quick action of drugs, widespread applications in treatment of diabetes, cancer, and hormone-related conditions has helped the segment maintain its dominance in the market.

Oral segment expects the fastest growth in the market during the forecast period. Because patients prefer non-invasive and convenient treatments, the improvements in drug delivery systems have enhanced the stability and absorption capacity of peptides administrated orally, the increasing availability of oral delivered peptides drugs and hydration compliance are other contributing factors.

Peptide Therapeutics Market Revenue (USD Million), By Route of Administration, 2022-2024

Distribution Channel Insights

Why the Hospital Pharmacies Segment Dominates the Peptide Therapeutics Market?

The hospital pharmacies segment dominated the peptide therapeutics market in 2025, Due to most peptide drugs need professional management and handling, Hospitals act as the main treatment centres for many difficult-to- Treat Chronic conditions, thus Resulting in more prescriptions, The high influx Of patients and availability of advanced treatments help explain why this segment is highly dominant in the market.

Online Drug Stores segment expects the fastest growth in the market during the forecast period. Because of the increasing trend of using healthcare online along with the benefit of having credits delivered at home, the increased use of the internet, easy availability of prescription drugs, and competitive pricing are encouraging patients to buy peptides from online pharmacies.

Synthesis Technology Insights

Why the Liquid Phase Peptide Synthesis (LPPS) Segment Dominates the Peptide Therapeutics Market?

The liquid phase peptide synthesis (LPPS) segment dominated the peptide therapeutics market in 2025. Because of its ability to facilitate bulk manufacturing and production of high purity peptides, the process has been extensively adopted in the manufacturing of peptides because of its efficiency in process control, scalability, and economic advantage in the certain peptides.

Solid-phase-synthesized peptides segment expects the fastest growth in the market during the forecast period. Due to rapid growing within the peptide therapeutic market as it allows the creation of complex peptides at high purity levels, the development of automated recruitment and quicker production process, as well as increased need for peptide drug discovery, have been fuelling its popularity.

Market Regional Analysis: North America, Europe, Asia-Pacific

Why North America is Dominating the Peptide Therapeutics Market?

North America Dominate Peptide Therapeutics Market, Due to the robust research setups in pharmaceutical industry, high expenditure on healthcare, and presence of leading players in the biotechnology industry, this is mainly because of the rising adoption of advanced peptide therapeutics, substantial investment in R and D, positive government regulations, and increased demand for chronic disease treatment.

The development of the biotechnology and pharmaceutical industries has fueled market growth in North America. Europe shows potential market growth for peptides in the region. The well-established healthcare industry in Europe is considered a significant factor in the development of the market. However, high-priced peptide drugs in Europe hamper the growth of the market.

U.S. Peptide Therapeutics Market Trends

Due to the availability of unadvanced healthcare system, biotechnological research, and innovation in medicines, an increase in the number of metabolic disorders, cancers, and chronic diseases, along with pharmaceutical investment in this segment, are contributing towards the growth of the market.

U.S. Peptide Therapeutics Market Size and Forecast 2026 to 2035

The U.S. peptide therapeutics market size is estimated at USD 21.24 billion in 2025 and is anticipated to reach around USD 34.98 billion by 2035, with a CAGR of 5.12% from 2026 to 2035.

Asia Pacific Peptide Therapeutics Market Trends

Asia Pacific expects the fastest growth in the market during the forecast period, due to growing investment in healthcare, growing incidence of chronic diseases, and growing capabilities in the manufacturing of pharmaceuticals, research activities, improved health care infrastructure, growing demand for better therapy, add use of biologics in countries like China, India and Japan are driving market growth in the region.

The rising development of novel peptide drugs for treating respiratory disorders and increasing investments in R&D activities propel the growth of the peptide therapeutics market in Latin America. Brazil is expected to dominate the peptide therapeutics market owing to the country's increased number of peptide therapies. Moreover, rapid adoption and increased awareness of peptide therapies in the Middle East and Africa will boost the demand for peptide therapeutics in these regions during the forecast period.

• In February 2025, to expand peptide therapeutics and CDMO capabilities, Granules India signed an acquisition agreement with a Switzerland-based Senn Chemicals AG, a contract development and manufacturing organization (CDMO) specializing in peptides. The acquisition, expected to close in the first half of 2025, is subject to specific conditions.

China Peptide Therapeutics Market Trends

Because of an increase in patients with chronic diseases, increasing spending on health care, and advancements in biotech research, support from the government towards pharmaceutical innovations, improvement in drug discovery abilities, and adoption of new treatments for conditions such as diabetes, cancer, and metabolic problems have led to the demand for peptide drugs.

Europe Expects the Significant Growth in the Market

Because of the rising demand for targeted medicines, higher incidences of chronic diseases, and active research on pharmaceuticals in the region, favourable healthcare policies, rising investments in biotechnology, clinical trial growth, and the adoption of peptides to treat cancer, diabetes and other diseases will boost market growth in Europe.

Germany Peptide Therapeutics Market Trends

Due to growing to the presence of a highly evolved pharmaceutical research environment, well- established healthcare infrastructure, and increased emphasis on innovations in biologics therapies, increase instances of diabetes, cancer, and other chronic illnesses are fuelling the demand for peptide therapeutics.

Middle East Expects the Significant Growth in the Market

Because of the increased investments in healthcare, increased cases of chronic disease, and improved access to medical treatment facilities, the developments in the field of pharmaceuticals, healthcare infrastructural development, and increased knowledge about the use of targeted therapies have contributed to the uptake of five peptides.

UAE Peptide Therapeutics Market Trends

Because witnessing growth on account of well-developed healthcare infrastructure, increased healthcare spending, and increasing demand for novel treatment, increased number of cases of metabolic disorder and chronic illness, and government efforts towards promoting innovation in pharmaceutical industry and biotechnology, have led to the use of peptides therapies.

Saudi Arabia

Saudi Arabia currently has the largest peptide therapeutics market within the Middle East and Africa because of its investment in healthcare-related infrastructure and the continuing trend toward advanced treatment options. Through national health programs and hospital modernization, Saudi Arabia is creating greater access to specialty medicines through hospitals; thus there is a growing demand for innovative therapy and an increased level of cooperation between global pharmaceutical companies with respect to the introduction of peptide-based therapies; therefore, Saudi Arabia should continue on its path to be one of the fastest-growing areas within the region.

Latin America's Valuable Business Deals in the Peptide Therapeutics Market

Latin America is expected to grow at a notable CAGR during the forecast period, as business deals are tied by the billions of megaproject deals in the subregions that feature the best of regional healthcare giants' innovation and smooth interventions in international approaches. This is an advantage, changing the whole picture of clinical trials, wellness and biopharma manufacturing. Novo Nordisk is a popular investor in the market responsible for the milestones of Ozempic and Wegovy. The billions of investments strengthening the facilities and across the delivery space are a boon to endocrine and metabolic therapies.

The aesthetic trends in the wellness sector feature cosmetics and skincare that eventually spike the dominance of the regional market in the beauty industry as well. The smart and expanded alliances of the brands and wellness enthusiasts to accelerate the craze of medical spas and contribute to the telehealth platforms are promoting investment ideas. Whereas the expanding biotech and clinical trials excellence confirms more space and impactful development, with the massive spending of the emerging companies and regulatory bodies, meeting the rapid need for effective solutions in the rising extreme health conditions.

Mexico Market Trends

The Mexican market is driven by massive demand for cardiometabolic therapy and fine strength to API manufacturing. The growing prevalence of obesity and type-2 diabetes accelerated the growing trend and solution of related metabolic peptide therapies. Valuable partnerships and research are bolstering Mexican research engagements and distributors. The regulatory peptide research has elevated the mechanisms accompanying the latest transitional trends. The dominance of generic and biosimilar solutions is an encouragement to the local market leaders, supporting the market with the improved accessibility of the cost-effective alternatives. The modern peptide-based treatments highlight the capitalizing ideas and efforts of the biotechnology firms and institutional investors.

Brazil Peptide Therapeutics Market trends

Because of the rising health care in requirements, increasing cases of diabetes, obesity and other chronic diseases, the improvements in the healthcare infrastructure, decreasing number of pharmaceutical researches, and use of advanced biological treatments are some of the reasons behind the expansion of the market.

Market Competitive Landscape: Leading Companies and Strategies

The peptide therapeutics market is a combined effort of the healthcare leaders, regulatory bodies and innovators. The modernization in biological and chemical synthesis is reframing the market dynamics since sustainability trends are a sincere development in the healthcare spectrum. The market champions include Novo Nordisk, Eli Lilly, Novartis, Bachem Holding, and AstraZeneca. The companies are following trends in computational modelling, peptide-drug conjugates, and oral delivery platforms.

Novartis is a well-known face of radiolabeled peptides and targeted oncology therapeutics, with further spending on peptide receptor radionuclide therapy proving to be a best-in-class financial backing in healthcare. Eli Lilly is known for Zepbound and Mounjaro, involving best-in-class research in the novel triple-agonists.

Supply Chain Analysis - Peptide Therapeutics Market

• R&D – The transition and prime advancements in the treatments ensure innovations meet the required clinical standards, serving as a shield for the peptides.
  Key Players – Lonza, Bachem, and PolyPeptide Group.
• Clinical Trials and Regulatory Approval – The growth and development of peptide therapeutics rely on these pathways to drive discovery and market commercial profit to assess the effectiveness and safety of the peptide. Various phases and regulatory standards bring advocacy and validation to market advancement and innovation.
  Key Players – IQVIA, ICON plc, Agilent Technologies, Fortrea, and Medidata
• Distribution to Hospitals, Pharmacies – The peptide therapeutics distribution to hospitals and pharmacies is accelerated by the modern blend in targeted, oncologic and metabolic therapies. The dominance of infusions and injectables is an add-on value to the market footprint in the hospital and pharmacy settings.
  Key Players – CordenPharma, Eli Lilly and Novo Nordisk.

Peptide Therapeutics Market Companies

• Eli Lilly & Company
• Amgen Inc.
• Pfizer, Inc.
• Ever Neuro Pharma GmbH
• Bausch Health
• Abbvie

Segments Covered in the Report

By Application

• Gastrointestinal Disorder
• Metabolic Disorder
• Neurological Disorder
• Cancer
• Others

By Type

• Generic
• Innovative

By Route of Administration

• Oral
• Parenteral
• Pulmonary
• Mucosal
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Drug Stores

By Synthesis Technology

• Solid Phase Peptide Synthesis (SPPS)
• Liquid Phase Peptide Synthesis (LPPS)
• Hybrid Technology

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa